PATH Malaria Vaccine Initiative
Request for quote for drug product manufacture: fill/finish of monoclonal antibody
The PATH Malaria Vaccine Initiative works to accelerate the development of promising malaria vaccines and catalyze their availability and accessibility in the developing world. As part of this work, PATH is developing two human monoclonal antibodies for phase 1 clinical trials in the US and Europe. In each case, the manufacturing of drug substance has begun and is expected to be completed by January 2018. PATH is seeking a GMP contractor to fill these products, perform testing and stability studies, provide primary labeling and bulk packaging, and possibly provide frozen storage of the product, as detailed in the RFQ.
Interested and qualified parties are encouraged to review the RFQ and confirm their interest no later than February 20, 2017. Subsequent proposals are due by March 30, 2017.
All of our requests for proposals adhere to our principles for procurement operations.